The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Abstract

Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer. Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age.

• Authors: Vibeke Kruse, Hannelore Denys, Rudy Van Den Broecke, Simon Van Belle, Veronique Cocquyt
• Journal: SpringerPlus (Springerplus) Vol. 2 Issue 1 Pg. 202 (Dec 2013) ISSN: 2193-1801 [Print] Switzerland
• PMID: 23710429 (Publication Type: Journal Article)